46
Views
1
CrossRef citations to date
0
Altmetric
Review

Management of metastatic renal cell carcinoma in patients with poor prognosis

, &
Pages 123-132 | Published online: 24 May 2010

References

  • JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
  • LamJSLeppertJTBelldegrunASFiglinRANovel approaches in the therapy of metastatic renal cell carcinomaWorld J Urol200523320221215812574
  • JanzenNKKimHLFiglinRABelldegrunASSurveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent diseaseUrol Clin North Am200330484385214680319
  • MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol200220128929611773181
  • MotzerRJBanderNHNanusDMRenal-cell carcinomaN Engl J Med1996335128658758778606
  • MotzerRJMazumdarMBacikJBergWAmsterdamAFerraraJSurvival and prognostic stratification of 670 patients with advanced renal cell carcinomaJ Clin Oncol19991782530254010561319
  • FlaniganRCSalmonSEBlumensteinBANephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancerN Engl J Med2001345231655165911759643
  • MickischGHGarinAvan PoppelHde PrijckLSylvesterRRadical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialLancet2001358928696697011583750
  • MekhailTMAbou-JawdeRMBoumerhiGValidation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinomaJ Clin Oncol200523483284115681528
  • NegrierSGomezFDouillardJYPrognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’ImmunotherapieWorld J Urol200523316116515711829
  • ChoueiriTKGarciaJAElsonPClinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyCancer2007110354355017577222
  • HengDYXieWReganMMPrognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyJ Clin Oncol2009
  • ZismanAPantuckAJDoreyFImproved prognostication of renal cell carcinoma using an integrated staging systemJ Clin Oncol20011961649165711250993
  • PatardJJLerayERioux-LeclercqNPrognostic value of histologic subtypes in renal cell carcinoma: a multicenter experienceJ Clin Oncol200523122763277115837991
  • FrankIBluteMLChevilleJCLohseCMWeaverALZinckeHAn outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN scoreJ Urol200216862395240012441925
  • LeibovichBCHanKRBuiMHScoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trialsCancer200398122566257514669275
  • ManiSToddMBKatzKPooWJPrognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiersJ Urol1995154135407539867
  • de Peralta-VenturinaMMochHAminMSarcomatoid differentiation in renal cell carcinoma: a study of 101 casesAm J Surg Pathol200125327528411224597
  • EscudierBDrozJPRollandFDoxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersJ Urol2002168395996112187199
  • ChevilleJCLohseCMZinckeHWeaverALBluteMLComparisons of outcome and prognostic features among histologic subtypes of renal cell carcinomaAm J Surg Pathol200327561262412717246
  • KimHLSeligsonDLiuXUsing tumor markers to predict the survival of patients with metastatic renal cell carcinomaJ Urol200517351496150115821467
  • LeibovichBCSheininYLohseCMCarbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinomaJ Clin Oncol200725304757476417947723
  • BuiMHVisapaaHSeligsonDPrognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinomaJ Urol20041716 Pt 12461246615126876
  • BuiMHSeligsonDHanKRCarbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapyClin Cancer Res20039280281112576453
  • AtkinsMReganMMcDermottDCarbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancerClin Cancer Res200511103714372115897568
  • ChoueiriTKVaziriSAJaegerEvon Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinomaJ Urol20081803860865 discussion 865–86618635227
  • SmitsKMSchoutenLJvan DijkBAGenetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosisClin Cancer Res200814378278718245539
  • PatardJJFergelotPKarakiewiczPILow CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinomaInt J Cancer2008123239540018464292
  • HoriguchiAOyaMUchidaAMarumoKMuraiMElevated Akt activation and its impact on clinicopathological features of renal cell carcinomaJ Urol2003169271071312544348
  • HoffmannNESheininYLohseCMExternal validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinomaCancer200811271471147918260086
  • ThompsonRZXHohseCMSerum soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage2008 Genitourinary Cancers Symposium2008 abstr 383.
  • ThompsonRH ZXLohseCMEvaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinomaJ Clin Oncol2008 ASCO Annual Meeting2008520 suppl abstr 5052.
  • NegrierSPerolDRavaudAMedroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trialCancer2007110112468247717932908
  • AtkinsMBHidalgoMStadlerWMRandomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaJ Clin Oncol200422590991814990647
  • HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
  • MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
  • MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
  • EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
  • RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol200826335422542818936475
  • SternbergCNSzczylikCLeeEA randomized, double-blind, phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)J Clin Oncol20092715s Abstr 5021.
  • MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
  • MotzerRJMichaelsonMDRedmanBGActivity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaJ Clin Oncol2006241162416330672
  • GoreMESzczylikCPortaCSafety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialLancet Oncol200910875776319615940
  • RiniBIVogelzangNJDumasMCWadeJL3rdTaberDAStadlerWMPhase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancerJ Clin Oncol200018122419242610856102
  • NanusDMGarinoAMilowskyMILarkinMDutcherJPActive chemotherapy for sarcomatoid and rapidly progressing renal cell carcinomaCancer200410171545155115378501
  • N HaasJMPinsMLiuGECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid featuresGenitourinary Cancers Symposium2009 abstr 285.
  • MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
  • HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
  • GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
  • SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
  • ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
  • KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
  • MichaelsonASRyanDMcDermottDA phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumorsGenitourinary Cancers Symposium 2008 abstr 362.
  • SchoutenLJRuttenJHuveneersHATwijnstraAIncidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanomaCancer200294102698270512173339
  • PatynaSLairdADMendelDBSU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activityMol Cancer Ther2006571774178216891463
  • RiechelmannRPChinSWangLSorafenib for metastatic renal cancer: the Princess Margaret experienceAm J Clin Oncol200831218218718391604
  • EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
  • JJ KnoxRAFStadlerWMMcDermottDFThe Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacyJ Clin Oncol2007 ASCO Annual Meeting Proceedings200725 18S620 Supplement
  • BukowskiRMPrognostic factors for survival in metastatic renal cell carcinoma: update 2008Cancer200911510 Suppl2273228119402065